When Klaus Sindahl joined Swedish biotech company Hansa Biopharma in 2019, the firm was still small, with a team of 40 people and no approved products.
Until then, and since the firm’s IPO on the Nasdaq Stockholm stock exchange in 2015, IR-related practices had been mostly outsourced, Sindahl explains, and the company was getting research coverage only through a few banks.
‘I saw an immediate need to bring communications back in-house to ensure we were relaying a consistent message while introducing the company to potential new investors and sell-side analysts,’ he tells IR Magazine.
‘We had . . .
Log in FOR FREE to access this content
Log in or create your free My IR – Essentials account to:
- Access 50+ deep dives and best practice reports
- View 100+ news analyses and our exclusive CFO series
- Instantly benchmark your IR program with our new tool
- Save favorites and get tailored content delivered to your dashboard
- 10% off all IR forums!
Join now to make a real impact in your organization.
